Can a seizure drug outsmart a deadly brain tumor?

NCT ID NCT07758062

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether adding levetiracetam, a seizure medication, to the standard treatment for glioblastoma can improve outcomes. Glioblastoma is an aggressive brain cancer with poor survival despite current therapy. The study focuses on tumors with low oxygen levels, which are linked to treatment resistance. Participants receive either levetiracetam plus standard chemo-radiation or standard treatment alone, and researchers will compare how long patients live without the cancer progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Levetiracetam extended-release granules added to the standard Stupp regimen (temozolomide plus radiotherapy)
What this could lead to
If it works, adding levetiracetam to standard treatment could slow tumor growth and extend survival for people with a hard-to-treat brain cancer.
What could go wrong
This is a phase 2 trial, so results are preliminary. The drug may not improve outcomes, and side effects could offset any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.